[1] Pinato DJ,Karamanakos G,Arizumi T,et al. Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma:a prospective study. Aliment Pharmacol Ther,2014,40(11-12):1270-1281. [2] Wang W,Shi J,Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma:a meta-analysis. Liver Int,2010,30(5):741-749. [3] Li MQ,Lu CH,Cheng J,et al. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroen Hepatol,2009,24(8):1437-1444. [4] Wu J,Ng J,Christos PJ,et al. Chronic thalidomide and chemoembolization for hepatocellular carcinoma. Oncologist,2014,19(12):1229-1230. [5] Britten CD,Gomes AS,Wainberg ZA,et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer:A pilot study. BMC Cancer, 2012,12:16. [6] Tong H,Li X,Zhang CL,et al. Octreotide and celecoxib synergistically encapsulate VX2 hepatic allografts following transcatheter arterial embolisation. Exp Ther Med,2013,5(3):777-782. [7] Tong H,Li X,Zhang CL,et al. Transcatheter arterial embolization followed by octreotide and celecoxib synergistically prolongs survival of rabbits with hepatic VX2 allografts. J Dig Dis,2013,14:29-37. |